The main challenge in RNA-sequencing workflow is certainly library preparation. When it’s question of single-cell isolation and so 10-100 picogram of total RNA, the challenge may become mission impossible… Today, we’re pleased to present a smart and simple device, to solve both single cell isolation and to help with library preparation.

Following the success of the previous EpiCypher meetings, we’re pleased to announce this year’s meeting by one of our partners EpiCypher.

EpiCypher2018: Biological and Clinical Frontiers in Epigenetics will feature keynote addresses by Dr. C. David Allis and Dr. Kristian Helin.

Dr. Allis is the Joy and Jack Fishman Professor and Head of the Laboratory of Chromatin Biology and Epigenetics at The Rockefeller University. Dr. Helin is a Professor at the University of Copenhagen and the director of the Danish National Research Foundation’s Centre for Epigenetics.

The plenary session talks will cover broad aspects of epigenetics and chromatin biology, ranging from basic molecular mechanisms to therapeutic efforts. There will be discussions around the elucidation of novel mechanisms, new tools, and other breaking topics in epigenetics and chromatin research.

Learn more about the meeting – download the flyer here.

As mentioned in a previous post the DAX Biochips from AIM Biotech are an innovative and versatile microfluidic platform, allowing researchers to more easily develop 3D cell culture models, to work as close as possible to what occurs in the human body, but under in-vitro conditions.

Due to its innovative structure (as seen in this general AIM Chips flyer), a broad range of applications have already been validated on this model (Cellular Migration-Invasion Analysis / Angiogenesis studies / Metstasis Modeling System), but what’s new is that now Immunotherapy and T-Cell Therapy studies can be performed on this technology.

Nipah Virus Infection (NiV) is an emerging infectious disease of public health importance in the South-East Asia Region (source: World Health Organization). Along with Hendra virus (HeV), NiV is part of a new genus designated Henipavirus. Fruit bats have been identified as the natural reservoirs. Nevertheless, pigs, horses, goats, sheep, cats and dogs can also be infected and transmit the virus.

Symptoms of NiV infection are similar to influenza and in some cases can lead to encephalitis. The case fatality rate is high (40-70%) and there is no specific treatment. While able to bind with cellular EphrinB2, NiV G Protein (NiV-G) exhibits the antigenic epitopes and conformation necessary for specific antigen–antibody recognition. For this reason, Meridian Life Science have recently developed new Nipah virus glycoprotein (NiV-G) products suitable for the R&D projects of NiV using ELISA tests.